Acute Myelogenous Leukemia

Velcade for Graft Versus Host DIsease – pro

Koreth found that Velcade was beneficial in GVHD; but his was a phase II trial and other phase II trials are ongoing. He found that i the 45 patients who were treated in the study; 89% of patients were treated with a one-locus and 11% of patients were treated with a two-loci mismatch. With a median follow-up of 3 years, the 180-day cumulative incidence of grade 2 to 4 acute GVHD was 22%, and the 1-year cumulative incidence of chronic GVHD was 29%.

Read more
Topical cidofovir in immunocompromised patients – pro

VISTIDE (cidofovir) is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). The FDA says: "THE SAFETY AND EFFICACY OF VISTIDE (cidofovir) HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS." It is a nephrotoxoc drug and cannot be administered to people with kidney

Read more
Promacta for AML or MDS – pro

Thrombocytopenia is a frequent symptom in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new option to treat thrombocytopenia in these diseases, provided that it can be shown does not stimulate malignant hematopoiesis. Unfortunately, there is no significant literature to support Promacta in the setting of ongoing treatment for AML or in

Read more
Acute myelogenous leukemia: Overview of treatment options – pro

Lay Summary: I review standard approaches to AML Standard Therapy of of acute myelogenous leukemia (excluding acute promyelocytic leukemia).Induction therapy: Various acceptable induction regimens are available. The most common approach is called ”3 and 7,” which consists of 3 days of a 15- to 30-minute infusion of an anthracycline (idarubicin or daunorubicin) or anthracenedione (mitoxantrone), combined with 100 mg/m2 of arabinosylcytosine (araC)

Read more
Allogeneic after failure of autologous or allogeneic transplant for AML – pro

A 2000 TEC assessment focused on high-dose chemotherapy and allogeneic stem cell support after a prior failed course of high-dose chemotherapy and autologous stem cell support, in the treatment of a variety of malignancies, including AML. The TEC Assessment found insufficient data to permit conclusions about this treatment strategy. A small series of pediatric patients (n=23) treated in this fashion has been published since that Assessment. The study

Read more
PCR regimen for CLL – pro

Lay Summary: Purine analogues and the PCR regimen are effective in CLL. When purine analogs were first introduced in the treatment ofpatients with CLL, the issue of whether or not these agentsshowed cross-resistance was a matter of extensive debate. Thecurrent notion is that cross-resistance does exist. However,pentostatin combined with cyclophosphamide has been reportedto produce responses (77% including one CR) in a small seriesof 13 patients who

Read more
CLAG for Acute Myelogenous Leukemia – pro

Lay Summary: CLAG and purine analogs for AML are reviewed. The purine nucleoside analogues (PNA), fludarabine (FA), cladribine (2-chlorodeoxyadenosine, 2-CdA) and 2'-deoxycoformycin (DCF), represent a novel group of cytotoxic agents with high activity in low-grade lymphoid malignancies. However, several investigations have revealed that these agents are active also in acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML). Synergistic

Read more
Allogeneic transplant for AML in 1st remission – pro

Lay Summary: Role of allogeneic transplantation in AML depends of underlying risk of recurrence. Allogeneic bone marrow transplantation results in the lowest incidence of leukemic relapse, even when compared with bone marrow transplantation from an identical twin (syngeneic bone marrow transplantation). This has led to the concept of an immunologic graft-versus-leukemia effect, similar to (and related to) graft-versus-host disease. The improvement

Read more
Stem Cell Transplant for refractory acute myelogenous leukemia – pro

There has recently been a paradigm shift in how oncologists think about refractory AML, disease in which there was no meaningful response and which is therefore resistant to standard chemotherapy. Refractory and relapsed disease occurs in many acute myelogenous leukemia patients. Salvage chemotherapy offers a 30–70% chance of a second complete remission. Unfortunately, this second remission is usually short lived and salvage chemotherapy is rarely

Read more
Vidaza and Myelotarg for acute meylogenous leukemia – pro

On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension (Vidaza) for treatment of patients with the following MDS subtypes: RA or RARS (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), RAEB, RAEB-T, and CMML. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome. It is now in trials for acute meyelogenous leukemia - AML. Subset analysis of the international

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39